Ռիկոզիբ-120

Հիմնական տեղեկություններ

  • Ֆիրմային անվանումը:
  • Ռիկոզիբ-120
  • INN (Միջազգային անվանումը):
  • sort of
  • Դոզան:
  • 120մգ(30/3x10/), բլիստերում
  • Դեղագործական ձեւ:
  • դեղահատեր թաղանթապատ
  • Ռեկվիզորի տեսակը:
  • Դեղատոմսով
  • Բժշկության տիրույթում:
  • Մարդիկ
  • Բժշկության տեսակ:
  • Ալլոպատիկ դեղամիջոց

Փաստաթղթեր

  • Հանրության համար:
  • Այս ապրանքի տեղեկատվական թերթիկը ներկայումս մատչելի չէ, դուք կարող եք խնդրանքը ուղարկել մեր հաճախորդների սպասարկմանը եւ մենք կտեղեկացնենք այն ժամանակ, երբ մենք կարող ենք ձեռք բերել այն:


    Տեղեկատվության թերթիկից պահանջել հանրությանը:

Տեղայնացումը

  • Հասանելի է:
  • Ռիկոզիբ-120
    አርሜኒያ
  • Լեզու:
  • አማርኛ

Այլ տեղեկություններ

Կարգավիճակը

  • Աղբյուրը:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • Վերջին թարմացումը:
  • 31-05-2018
  • Այս ապրանքի տեղեկատվական թերթիկը ներկայումս մատչելի չէ, դուք կարող եք խնդրանքը ուղարկել մեր հաճախորդների սպասարկմանը եւ մենք կտեղեկացնենք այն ժամանակ, երբ մենք կարող ենք ձեռք բերել այն:

    Տեղեկատվության թերթիկից պահանջել հանրությանը:



  • Այլ լեզուներով փաստաթղթերը հասանելի են Այստեղ
  • Այս փաստաթուղթը հասանելի է միայն գրանցված օգտագործողների համար:

    Register now for full access

12-12-2018

White-Rodgers recalls First-Generation Emerson branded Sensi Wi-Fi Thermostats

White-Rodgers recalls First-Generation Emerson branded Sensi Wi-Fi Thermostats

The thermostat can be damaged by household line voltage (120 volts or 240 volts) during service or replacement of a heating or cooling system, posing a fire hazard.

Health Canada

20-10-2018

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Scientific Opinion on Flavouring Group Evaluation 200, Revision 1 (FGE.200 Rev.1): 74 α,β‐unsaturated aliphatic aldehydes and precursors from chemical subgroup 1.1.1 of FGE.19

Published on: Fri, 19 Oct 2018 00:00:00 +0200 The Panel on Food Additives and Flavourings of the European Food Safety Authority was requested to evaluate the genotoxic potential of 74 flavouring substances from subgroup 1.1.1 of FGE.19 in the Flavouring Group Evaluation 200 Revision 1 (FGE.200 Rev1). In FGE.200, genotoxicity studies were provided for one representative substance, namely hex‐2(trans)‐enal [FL‐no: 05.073], and for other two substances in the same subgroup, namely 2‐dodecenal [FL‐no: 05.03...

Europe - EFSA - European Food Safety Authority Publications

20-9-2018

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Siu & Sons Int'l Trading recalls Color Fantastik Assorted Rubber Animal Toys

Health Canada's sampling and evaluation program has determined that the rubber animals do not meet the Canadian safety requirements for toys. The squeakers inside the rubber animals can be easily removed; these small parts pose a choking hazard to young children.

Health Canada

12-9-2018

FDA awards five grants to advance the development of pediatric medical devices

FDA awards five grants to advance the development of pediatric medical devices

FDA has awarded grants to five Pediatric Device Consortia that will provide advice to innovators of children's medical devices

FDA - U.S. Food and Drug Administration

10-8-2018

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration

Westminster Pharmaceuticals, LLC is voluntarily recalling all lots, within expiry, of Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s Import Alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with Current Good Ma...

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

6-4-2018

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

"Organic Traditions Shatavari Powder" sold at Choices Markets Yaletown in Vancouver, B.C., contaminated with Salmonella

Health Canada is advising Canadians that one lot of “Organic Traditions Shatavari Powder” is being voluntarily recalled by Advantage Health Matters Inc. Company testing found Salmonella bacteria contamination, which may pose serious health risks. According to Advantage Health Matters Inc., 13 units from the affected lot were distributed. Of the 13 units, only 2 packages, sold at Choices Markets Yaletown (1202 Richards Street) in Vancouver, B.C., have not been recovered.

Health Canada

22-11-2018

Selincro (H. Lundbeck A/S)

Selincro (H. Lundbeck A/S)

Selincro (Active substance: nalmefene) - PSUSA - Modification - Commission Decision (2018)7889 of Thu, 22 Nov 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10120/201802

Europe -DG Health and Food Safety

9-11-2018

TGA presentation: Generic and Biosimilar Medicines Association (GBMA) meeting, 2 November 2018

TGA presentation: Generic and Biosimilar Medicines Association (GBMA) meeting, 2 November 2018

Short presentation on the ACSS Consortium, the Generic Medicines Working Group and the Generic Medicines Work-Sharing Trial

Therapeutic Goods Administration - Australia

31-7-2018

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date.  Learn more about the PDC here:  https://go.usa.gov/xUvBC  #Pediatrics #Med

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date. Learn more about the PDC here: https://go.usa.gov/xUvBC  #Pediatrics #Med

FDA’s Pediatric Device Consortia Grant Program (PDC) facilitates the development, of medical devices for children. 18 pediatric medical devices have been approved/cleared to date. Learn more about the PDC here: https://go.usa.gov/xUvBC  #Pediatrics #MedicalDevice #FDA pic.twitter.com/HgMSCIbmra

FDA - U.S. Food and Drug Administration

19-7-2018

Regulatory and procedural guideline:  Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Regulatory and procedural guideline: Qualification opinion on dopamine transporter imaging as an enrichment biomarker for Parkinson’s disease clinical trials in patients with early Parkinsonian symptoms, adopted

Critical Path Global Ltd.’s Critical Path for Parkinson’s (CPP) is a multinational consortium of the Critical Path Institute supported by Parkinson’s UK and industry. This broad collaboration of pharmaceutical companies, government agencies, academic institutions, and charities aims to accelerate the development of therapies for Parkinson’s disease (PD).

Europe - EMA - European Medicines Agency

10-7-2018

Revolade (Novartis Europharm Limited)

Revolade (Novartis Europharm Limited)

Revolade (Active substance: Eltrombopag) - PSUSA - Modification - Commission Decision (2018)4487 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/1205/201709

Europe -DG Health and Food Safety

5-7-2018

International work-sharing pilot - Apalutamide (Erlyand)

International work-sharing pilot - Apalutamide (Erlyand)

Apalutamide (Erlyand) is the first medicine approved via ACSS Consortium’s NCE working group

Therapeutic Goods Administration - Australia

14-6-2018

ACSS public statement, 27-28 October 2017

ACSS public statement, 27-28 October 2017

ACSS Consortium Generic Medicines Working Group public statement for Brazil meeting, October 2017

Therapeutic Goods Administration - Australia

6-6-2018

Prolia (Amgen Europe B.V.)

Prolia (Amgen Europe B.V.)

Prolia (Active substance: denosumab) - Centralised - 2-Monthly update - Commission Decision (2018) 3685 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1120/II/68

Europe -DG Health and Food Safety

16-5-2018

EU/3/14/1382 (Novartis Europharm Limited)

EU/3/14/1382 (Novartis Europharm Limited)

EU/3/14/1382 (Active substance: Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist) - Transfer of orphan designation - Commission Decision (2018)3044 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/120/14/T/01

Europe -DG Health and Food Safety

16-5-2018

EU/3/13/1205 (Novartis Europharm Limited)

EU/3/13/1205 (Novartis Europharm Limited)

EU/3/13/1205 (Active substance: Human monoclonal antibody against human interleukin 13) - Transfer of orphan designation - Commission Decision (2018)3042 of Wed, 16 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/118/13/T/01

Europe -DG Health and Food Safety